Names that match “Webmind Inc”
1,411 documents found
Third, the report highlights how powerful bipartisan constituencies have emerged in the past to
document IMAGES-006-HOUSE_OVERSIGHT_020827.txt House Oversight Committee — Epstein Estate Records (Nov 2025)
Third, the report highlights how powerful bipartisan constituencies have emerged in the past to
tackle great issues for the betterment of our nation, including tax reform, civil liberties,
healthcare, education and national defense. Just as presidents of both parties rose to the...
Bellingham, Washington
document IMAGES-008-HOUSE_OVERSIGHT_024794.txt House Oversight Committee — Epstein Estate Records (Nov 2025)
Or
>
A
“Bw
Plan
fon on
RO RUBICON
. . ORGANICS
Rubicon Organics
Bellingham, Washington
www.rubiconorganics.com
Rubicon Organics is a licensed cannabis culti-
vator specializing in the growing, processing,
packaging and marketing of cannabis. The com-
pany is developing greenho...
High-Level Thoughts on
document IMAGES-006-HOUSE_OVERSIGHT_020854.txt House Oversight Committee — Epstein Estate Records (Nov 2025)
High-Level Thoughts on
Income Statement/Balance Sheet
KP
CC —— USA Inc. | High Level Thoughts 25
How Would You Feel if...
...your Cash Flow was NEGATIVE for
each of the past 9 years...
... your Net Worth* has been
NEGATIVE for as long as you can
remember...
... t would take...
Paul J. Set Theory and the Continuum Hypothesis. Dover Publications Inc
document Cohen House Oversight Committee — Epstein Estate Records (Nov 2025)
Paul J. Set Theory and the Continuum Hypothesis. Dover Publications Inc.
USA Inc.’s financial liabilities -- whether they are actual
document e Unless they are reduced House Oversight Committee — Epstein Estate Records (Nov 2025)
USA Inc.’s financial liabilities -- whether they are actual
Inc. Therapeutics 7.7 19.4 - 19.4 2.51 2.51 581.9%
document Acadia Phamaceuticals House Oversight Committee — Epstein Estate Records (Nov 2025)
Inc. Therapeutics 7.7 19.4 - 19.4 2.51 2.51 581.9%
Inc. Therapeutics 2013 10.4 11.1 - 11.1 1.06 1.06 13.1%
document Ambit Biosciences House Oversight Committee — Epstein Estate Records (Nov 2025)
Inc. Therapeutics 2013 10.4 11.1 - 11.1 1.06 1.06 13.1%
Inc. Convergence 2011 88: 125 1.6 14.1 - 3.68 105.6%
document Audax Health Solutions House Oversight Committee — Epstein Estate Records (Nov 2025)
Inc. Convergence 2011 88: 125 1.6 14.1 - 3.68 105.6%
Inc. Therapeutics 2011 20.6 27.0 44.9 71.9 3.07 3.50 57.7%
document Chimerix House Oversight Committee — Epstein Estate Records (Nov 2025)
Inc. Therapeutics 2011 20.6 27.0 44.9 71.9 3.07 3.50 57.7%
Inc. Therapeutics 2013 3.4 6.8 - 6.8 2.03 2.03 1583.0%
document Epizyme House Oversight Committee — Epstein Estate Records (Nov 2025)
Inc. Therapeutics 2013 3.4 6.8 - 6.8 2.03 2.03 1583.0%
Inc. Diagnostics & Infrastructure 2008 10.7 - - - - - NM
document Glumetrics House Oversight Committee — Epstein Estate Records (Nov 2025)
Inc. Diagnostics & Infrastructure 2008 10.7 - - - - - NM
Inc. Therapeutics 2012 10.5 34.1 - 34.1 3.24 3.24 323.6%
document Intercept Pharmaceuticals House Oversight Committee — Epstein Estate Records (Nov 2025)
Inc. Therapeutics 2012 10.5 34.1 - 34.1 3.24 3.24 323.6%
Inc. Therapeutics 2011 2.4 02 - 0.2 0.07 0.07 -91.6%
document Kalidex Pharmaceuticals House Oversight Committee — Epstein Estate Records (Nov 2025)
Inc. Therapeutics 2011 2.4 02 - 0.2 0.07 0.07 -91.6%
Inc. Therapeutics 2012 9.0 10.2 35.8 46.0 2.94 5.12 423.2%
document MEI Pharma House Oversight Committee — Epstein Estate Records (Nov 2025)
Inc. Therapeutics 2012 9.0 10.2 35.8 46.0 2.94 5.12 423.2%
Inc. Therapeutics 2009 11.0 - - - - - NM
document Presidio Pharmaceuticals House Oversight Committee — Epstein Estate Records (Nov 2025)
Inc. Therapeutics 2009 11.0 - - - - - NM